Table 5. Multivariate analysis of age, ER-, PR-status, lymph node, grade and 92-probe signature in relation to the 5-year survival.
| Parameters | HR (95%CI) | p Value |
|---|---|---|
| Analysis without 92-probe signature | ||
| Age (years) | 0.984 (0.971–0.998) | 0.025 |
| ER status (+/–) | 0.510 (0.270–0.961) | 0.037 |
| PR status (+/–) | 0.905 (0.479–1.710) | 0.757 |
| Lymph node (+/–) | 1.517 (1.062–2.165) | 0.022 |
| Grade (1, 2, 3) | 1.708 (1.291–2.258) | <0.001 |
| Analysis with 92-probe signature | ||
| Age (years) | 0.984 (0.970–0.998) | 0.023 |
| ER status (+/–) | 0.878 (0.423–1.825) | 0.728 |
| PR status (+/–) | 0.974 (0.512–1.853) | 0.936 |
| Lymph node (+/–) | 1.539 (1.079–2.197) | 0.017 |
| Grade (1, 2, 3) | 1.562 (1.173–2.080) | 0.002 |
| 92-probe signature (low/high) | 2.239 (1.265–3.963) | 0.006 |
A low risk was defined as a prognostic index less than or equal to −0.272144, and a high risk as a PI higher than −0.272144. HR, hazard ratio; CI, confident interval; ER, estrogen receptor; PR, progesterone receptor.